FLEMINGTON, N.J.--(BUSINESS WIRE)--Aug. 30, 2006--NovaDel Pharma (AMEX: NVD) today announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Zensana(TM) (ondansetron HCl) Oral Spray which was submitted by Hana Biosciences, NovaDel’s North American partner for ondansetron oral spray, on June 30, 2006. This acceptance triggers the next payment in a series of milestone payments to NovaDel.
